Key Points
- Director sale: Alphatec Director David Pelizzon sold 250,000 shares on Dec. 16 at an average of $19.66 for about $4.915 million, trimming his stake by 2.35% while still owning 10,395,045 shares (~$204.37M).
- Recent results and stock metrics: Alphatec beat expectations with Q (Oct.) EPS of $0.03 vs. -$0.06 and revenue of $196.5M (+30.4% YoY); the stock trades near $19.87, has a 52-week range of $8.70–$22.66, and a market cap of ~$2.95B.
- Analyst view: The consensus rating is a "Moderate Buy" with a $22.45 average price target (majority Buy ratings), while several firms have $25 targets and Wells Fargo recently raised its target to $16.
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) Director David Pelizzon sold 250,000 shares of the firm's stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $19.66, for a total transaction of $4,915,000.00. Following the completion of the transaction, the director directly owned 10,395,045 shares in the company, valued at approximately $204,366,584.70. The trade was a 2.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Alphatec Stock Performance
Shares of Alphatec stock opened at $19.87 on Friday. Alphatec Holdings, Inc. has a 52 week low of $8.70 and a 52 week high of $22.66. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 43.02. The business has a 50 day moving average price of $18.90 and a 200-day moving average price of $15.29. The company has a market cap of $2.95 billion, a PE ratio of -19.11 and a beta of 1.08.
Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to analysts' expectations of $182.78 million. The firm's quarterly revenue was up 30.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.28) EPS. Equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on ATEC. Loop Capital set a $25.00 target price on shares of Alphatec in a report on Wednesday, December 10th. Lake Street Capital set a $25.00 target price on shares of Alphatec and gave the stock a "buy" rating in a research report on Friday, October 31st. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Alphatec in a report on Monday. Piper Sandler reiterated an "overweight" rating and set a $25.00 price target (up from $20.00) on shares of Alphatec in a report on Friday, October 31st. Finally, Wells Fargo & Company boosted their price objective on Alphatec from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Thursday, October 16th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Alphatec presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.45.
Check Out Our Latest Stock Report on Alphatec
Hedge Funds Weigh In On Alphatec
Several institutional investors and hedge funds have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd purchased a new stake in Alphatec in the third quarter worth $34,000. Osterweis Capital Management Inc. bought a new position in shares of Alphatec during the 2nd quarter worth $37,000. Nisa Investment Advisors LLC increased its holdings in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock worth $63,000 after acquiring an additional 1,045 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Alphatec in the 3rd quarter valued at about $73,000. Finally, FNY Investment Advisers LLC purchased a new stake in Alphatec during the third quarter valued at about $74,000. 66.35% of the stock is owned by institutional investors.
Alphatec Company Profile
(
Get Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
